Blog

Search results for 'Nicholi': Page 38

Apr 1, 2020

Stanford researchers develop potential method to reuse N95 respirators

Posted by in category: biotech/medical

A team of Stanford researchers may have found a way to use heat to disinfect N95 respirators, potentially enabling reuse of the single-use masks that are running dangerously low nationwide as the number of COVID-19 cases in the U.S. continues to grow.

The team’s research, based on experiments on a type of fabric commonly used in respirators and industrial-grade respirators, found that a 30-minute exposure to 75 °C could be used up to 20 times to disinfect N95 respirators without a loss of filtration efficiency and mechanical deformation.

These findings could be game-changing for both hospitals and individuals due to the method’s ease of use, said materials science and engineering professor Yi Cui, who led the research at 4C Air along with physics and molecular biology professor Steven Chu.

Mar 31, 2020

Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19

Posted by in category: biotech/medical

The coronavirus can travel up to 23–27 feet :


This JAMA Insights Clinical Update discusses the need to better understand the dynamics of respiratory disease transmission by better characterizing transmission routes, the role of patient physiology in shaping them, and best approaches for source control in the context of the COVID-19 outbreak.

Mar 31, 2020

Mind-reading AI turns thoughts into words using a brain implant

Posted by in categories: information science, robotics/AI

An artificial intelligence can accurately translate thoughts into sentences, at least for a limited vocabulary of 250 words. The system may bring us a step closer to restoring speech to people who have lost the ability because of paralysis.

Joseph Makin at the University of California, San Francisco, and his colleagues used deep learning algorithms to study the brain signals of four women as they spoke. The women, who all have epilepsy, already had electrodes attached to their brains to monitor seizures.

Mar 31, 2020

BREAKING: FDA Issues Emergency Authorization for Hydroxychloroquine to be Prescribed to Coronavirus Patients

Posted by in category: biotech/medical

** On Saturday Dr. Vladimir Zelenko reported that he has now successfully treated 699 COVID-19 patients in New York for the coronavirus. Dr. Zelenko reported 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.

** On Friday night the French research team led by the renowned epidemiologist Dr. Didier Raoult was able to repeat his findings from a previous study. Dr. Raoult administered hydroxychloroquine and azithromycin to 80 patients and observed improvement in EVERY CASE except for a very sick 86-year-old with an advanced form of coronavirus infection.

On Sunday night the FDA issued an emergency authorization for hydroxychloroquine to be prescribed to coronavirus patients.

Mar 31, 2020

Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing

Posted by in categories: biotech/medical, health

The newly emergent human virus SARS-CoV-2 is resulting in high fatality rates and incapacitated health systems. Preventing further transmission is a priority. We analyzed key parameters of epidemic spread to estimate the contribution of different transmission routes and determine requirements for case isolation and contact-tracing needed to stop the epidemic. We conclude that viral spread is too fast to be contained by manual contact tracing, but could be controlled if this process was faster, more efficient and happened at scale. A contact-tracing App which builds a memory of proximity contacts and immediately notifies contacts of positive cases can achieve epidemic control if used by enough people. By targeting recommendations to only those at risk, epidemics could be contained without need for mass quarantines (‘lock-downs’) that are harmful to society. We discuss the ethical requirements for an intervention of this kind.

COVID-19 is a rapidly spreading infectious disease caused by the novel coronavirus SARS-COV-2, a betacoronavirus, which has now established a global pandemic. Around half of infected individuals become reported cases, and with intensive care support, the case fatality rate is approximately 2%. More concerning is that the proportion of cases requiring intensive care support is 5%, and patient management is complicated by requirements to use personal protective equipment and engage in complex decontamination procedures. Fatality rates are likely to be higher in populations older than in Hubei province (such as in Europe), and in low-income settings where critical care facilities are lacking. In the public health cost of failing to achieve sustained epidemic suppression was estimated as 250,000 lives lost in the next few months in Great Britain, and 1.1−1.2 million in the USA, even with the strongest possible mitigation action to ‘flatten the curve’.

Mar 30, 2020

Some COVID-19 patients still have coronavirus after symptoms disappear

Posted by in category: biotech/medical

Just a quick update on a new study:

“Researchers found that half of the patients they treated for mild COVID-19 infection still had coronavirus for up to eight days after symptoms disappeared.”

“If you had mild respiratory symptoms from COVID-19 and were staying at home so as not to infect people, extend your quarantine for another two weeks after recovery to ensure that you don’t infect other people,” recommended corresponding author Lixin Xie, MD, professor, College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing.

Mar 29, 2020

Newly developed laboratory model helps reveal how HIV infection affects the brain

Posted by in categories: biotech/medical, neuroscience

Though many negative repercussions of human immunodeficiency virus infection can be mitigated with the use of antiretroviral therapy (ART), one area where medical advances haven’t made as much progress is in the reduction of cognitive impacts. Half of HIV patients have HIV-associated neurocognitive disorders (HAND), which can manifest in a variety of ways, from forgetfulness and confusion to behavior changes and motor deficiencies.

To better understand the mechanisms underlying HAND, researchers from Penn’s School of Dental Medicine and Perelman School of Medicine and from the Children’s Hospital of Philadelphia (CHOP) brought together their complementary expertise to create a laboratory model system using three of the types of brain cells thought to be involved. Led by doctoral student Sean Ryan, who was co-mentored by Kelly Jordan-Sciutto of Penn Dental Medicine and Stewart Anderson of CHOP and Penn Medicine, the model recapitulates important features of how HIV infection and ART affect the brain.

“Frankly the models we generally use in the HIV field have a lot of weaknesses,” says Jordan-Sciutto, co-corresponding author on the paper, which appears in the journal Stem Cell Reports. “The power of this system is it allows us to look at the interaction between different cell types of human origin in a way that is more relevant to patients than other models.”

Mar 28, 2020

From Bats to Human Lungs, the Evolution of a Coronavirus

Posted by in categories: biotech/medical, evolution, genetics

There are endless viruses in our midst, made either of RNA or DNA viruses, which exist in much greater abundance around the planet, are capable of causing systemic diseases that are endemic, latent, and persistent—like the herpes viruses (which includes chicken pox), hepatitis B, and the papilloma viruses that cause cancer. “DNA viruses are the ones that live with us and stay with us,” Denison said. “They’re lifelong.” Retroviruses, like H.I.V., have RNA in their genomes but behave like DNA viruses in the host. RNA viruses, on the other hand, have simpler structures and mutate rapidly. “Viruses mutate quickly, and they can retain advantageous traits,” Epstein told me. “A virus that’s more promiscuous, more generalist, that can inhabit and propagate in lots of other hosts ultimately has a better chance of surviving.” They also tend to cause epidemics—such as measles, Ebola, Zika, and a raft of respiratory infections, including influenza and coronaviruses. Paul Turner, a Rachel Carson professor of ecology and evolutionary biology at Yale University, told me, “They’re the ones that surprise us the most and do the most damage.”

Scientists discovered the coronavirus family in the nineteen-fifties, while peering through early electron microscopes at samples taken from chickens suffering from infectious bronchitis. The coronavirus’s RNA, its genetic code, is swathed in three different kinds of proteins, one of which decorates the virus’s surface with mushroom-like spikes, giving the virus the eponymous appearance of a crown. Scientists found other coronaviruses that caused disease in pigs and cows, and then, in the mid-nineteen-sixties, two more that caused a common cold in people. (Later, widespread screening identified two more human coronaviruses, responsible for colds.) These four common-cold viruses might have come, long ago, from animals, but they are now entirely human viruses, responsible for fifteen to thirty per cent of the seasonal colds in a given year. We are their natural reservoir, just as bats are the natural reservoir for hundreds of other coronaviruses. But, since they did not seem to cause severe disease, they were mostly ignored. In 2003, a conference for nidovirales (the taxonomic order under which coronaviruses fall) was nearly cancelled, due to lack of interest. Then SARS emerged, leaping from bats to civets to people. The conference sold out.

SARS is closely related to the new virus we currently face. Whereas common-cold coronaviruses tend to infect only the upper respiratory tract (mainly the nose and throat), making them highly contagious, SARS primarily infects the lower respiratory system (the lungs), and therefore causes a much more lethal disease, with a fatality rate of approximately ten per cent. (MERS, which emerged in Saudi Arabia, in 2012, and was transmitted from bats to camels to people, also caused severe disease in the lower respiratory system, with a thirty-seven per cent fatality rate.) SARS-CoV-2 behaves like a monstrous mutant hybrid of all the human coronaviruses that came before it. It can infect and replicate throughout our airways. “That’s why it is so bad,” Stanley Perlman, a professor of microbiology and immunology who has been studying coronaviruses for more than three decades, told me. “It has the lower-respiratory severity of SARS and MERS coronaviruses, and the transmissibility of cold coronaviruses.”

Mar 28, 2020

Would everyone wearing face masks help us slow the pandemic?

Posted by in categories: biotech/medical, health

Despite messages from some health officials to the contrary, it’s likely that a mask can help protect a healthy wearer from infection, says Benjamin Cowling, an epidemiologist at the University of Hong Kong. Both surgical masks and the more protective N95 respirators have been shown to prevent various respiratory infections in health care workers; there’s been some debate about which of the two is appropriate for different kinds of respiratory infection patient care. “It doesn’t make sense to imagine that … surgical masks are really important for health care workers but then not useful at all for the general public,” Cowling says.


Some argue that masking everyone would slow the spread of COVID-19—but the evidence is spotty.

Mar 28, 2020

Genentech Tests Tocilizumab (Used for Cytokine Release Syndrome in Myeloma CAR T Therapy) in Phase III Trial for Severe COVID-19

Posted by in category: biotech/medical

Genentech is working with the FDA to launch a Phase III study comparing tocilizumab (Actemra) vs. standard of care in hospitalized adult patients with severe COVID-19 pneumonia. The trial hopes to open in April 2020 and test 330 patients. The trial endpoints include clinical status, mortality, mechanical ventilation and ICU variables.

Tocilizumab is the first humanized interleukin-6 (IL-6) drug originally approved for rheumatoid arthritis and is now being tested in COVID-19 patients to reduce lung inflammation. The IV version is also approved for patients who have CAR T cell induced cytokine release syndrome (which includes many multiple myeloma patients.). High IL-6 levels can cause damaging inflammation and tocilizumab blocks the effects of IL-6.

According to Randy Cron, MD, PhD, an expert in cytokine release syndrome, some of the severely ill coronavirus patients have lab features of CRS, also sometimes called cytokine storm syndrome (CSS).

Page 38 of 58First36373839404142